Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1946 1
1955 1
1957 1
1962 5
1963 8
1964 4
1965 6
1966 6
1967 11
1968 6
1969 7
1970 4
1971 4
1972 9
1973 13
1974 5
1975 5
1976 13
1977 13
1978 13
1979 15
1980 24
1981 17
1982 13
1983 16
1984 23
1985 27
1986 18
1987 22
1988 18
1989 19
1990 20
1991 31
1992 36
1993 19
1994 18
1995 23
1996 15
1997 16
1998 19
1999 18
2000 28
2001 37
2002 45
2003 43
2004 61
2005 87
2006 91
2007 104
2008 98
2009 105
2010 147
2011 138
2012 175
2013 207
2014 206
2015 228
2016 222
2017 240
2018 258
2019 260
2020 310
2021 360
2022 373
2023 373
2024 79

Text availability

Article attribute

Article type

Publication date

Search Results

4,340 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Clinical Trial.
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Rini BI, et al. Among authors: pal sk. J Immunother Cancer. 2022 Dec;10(12):e005445. doi: 10.1136/jitc-2022-005445. J Immunother Cancer. 2022. PMID: 36549781 Free PMC article. Clinical Trial.
Lymphatic vasculature in ovarian cancer.
Pal S, Bhowmick S, Sharma A, Sierra-Fonseca JA, Mondal S, Afolabi F, Roy D. Pal S, et al. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188950. doi: 10.1016/j.bbcan.2023.188950. Epub 2023 Jul 5. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37419192 Review.
Cell-autonomous immune dysfunction driven by disrupted autophagy in C9orf72-ALS iPSC-derived microglia contributes to neurodegeneration.
Banerjee P, Mehta AR, Nirujogi RS, Cooper J, James OG, Nanda J, Longden J, Burr K, McDade K, Salzinger A, Paza E, Newton J, Story D, Pal S, Smith C, Alessi DR, Selvaraj BT, Priller J, Chandran S. Banerjee P, et al. Among authors: pal s. Sci Adv. 2023 Apr 21;9(16):eabq0651. doi: 10.1126/sciadv.abq0651. Epub 2023 Apr 21. Sci Adv. 2023. PMID: 37083530 Free PMC article.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Pal SK, et al. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099926 Clinical Trial.
Immuno-Oncology Advances in Genitourinary Cancers.
Zang PD, Angeles A, Dorff TB, Pal SK, Gupta S. Zang PD, et al. Among authors: pal sk. Am Soc Clin Oncol Educ Book. 2024 Jan;44(2):e430428. doi: 10.1200/EDBK_430428. Am Soc Clin Oncol Educ Book. 2024. PMID: 38206274 Free article. Review.
Emergent dynamics of adult stem cell lineages from single nucleus and single cell RNA-Seq of Drosophila testes.
Raz AA, Vida GS, Stern SR, Mahadevaraju S, Fingerhut JM, Viveiros JM, Pal S, Grey JR, Grace MR, Berry CW, Li H, Janssens J, Saelens W, Shao Z, Hu C, Yamashita YM, Przytycka T, Oliver B, Brill JA, Krause H, Matunis EL, White-Cooper H, DiNardo S, Fuller MT. Raz AA, et al. Among authors: pal s. Elife. 2023 Feb 16;12:e82201. doi: 10.7554/eLife.82201. Elife. 2023. PMID: 36795469 Free PMC article.
Defining the Mycobiome in Bladder Cancer.
Mercier BD, Castro DV, Pal SK. Mercier BD, et al. Among authors: pal sk. Eur Urol Open Sci. 2022 Dec 27;48:70-71. doi: 10.1016/j.euros.2022.11.023. eCollection 2023 Feb. Eur Urol Open Sci. 2022. PMID: 36606201 Free PMC article. No abstract available.
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: pal sk. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
4,340 results